Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice

Abstract

We have previously shown that BCR/ABL, a fusion protein generated by the t(9;22)(q34;q11) translocation found in the vast majority of chronic myelogenous leukemia (CML), cooperates with AML1/MDS1/EVI1 (AME), a fusion transcription factor generated by a t(3;21)(q26;q22) translocation identified as a secondary mutation in some cases of CML during the blast phase (CML-BC), in the rapid induction of an acute myelogenous leukemia (AML) in mice. In this study, we evaluated the leukemogenic potential of EVI1-, MDS1/EVI1- and AML1-related oncoproteins (AML1Δ, AML1/MDS1). We found that ectopic expression of either EVI1 or MDS1/EVI1 impaired hematopoiesis. However, neither EVI1 nor MDS1/EVI1 was sufficient for inducing AML in mice, although EVI1 did induce some hematologic neoplasia other than AML with a low efficiency. In addition, unlike AME, none of the EVI1- or AML1-related oncoproteins examined were capable of fully cooperating with BCR/ABL in the induction of AML. The results indicate that both the AML1 and EVI1 oncogenic components are required for the leukemogenic potential of AME and for the cooperation of AME and BCR/ABL in the induction of AML.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Castilla LH, Garrett L, Adya N, Orlic D, Dutra A, Anderson S, Owens J, Eckhaus M, Bodine D and Liu PP . (1999). Nat. Genet., 23, 144–146.

  • Castilla LH, Wijmenga C, Wang Q, Stacy T, Speck NA, Eckhaus M, Marin-Padilla M, Collins FS, Wynshaw-Boris A and Liu PP . (1996). Cell, 87, 687–696.

  • Cuenco GM, Nucifora G and Ren R . (2000). Proc. Natl. Acad. Sci. USA, 97, 1760–1765.

  • Cuenco GM and Ren R . (2001). Oncogene, 20, 8236–8248.

  • Erickson PF, Robinson M, Owens G and Drabkin HA . (1994). Cancer Res., 54, 1782–1786.

  • Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R and Kantarjian HM . (1999). N. Engl. J. Med., 341, 164–172.

  • Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD and Nucifora G . (1996). Proc. Natl. Acad. Sci. USA, 93, 1642–1647.

  • Fialkow PJ, Janssen JW and Bartram CR . (1991). Blood, 77, 1415–1417.

  • Gilliland DG and Griffin JD . (2002). Blood, 100, 1532–1542.

  • Hao SX and Ren R . (2000). Mol. Cell. Biol., 20, 1149–1161.

  • Huang S, Shao G and Liu L . (1998). J. Biol. Chem., 273, 15933–15939.

  • Izutsu K, Kurokawa M, Imai Y, Ichikawa M, Asai T, Maki K, Mitani K and Hirai H . (2002). Oncogene, 21, 2695–2703.

  • Jacobs A . (1991). Leukemia, 5, 277–282.

  • Kojima K, Yasukawa M, Ishimaru F, Dansako H, Matsuo Y, Kimura Y, Nawa Y, Hara M and Harada M . (1999). Br. J. Haematol., 106, 720–722.

  • Kreider BL, Orkin SH and Ihle JN . (1993). Proc. Natl. Acad. Sci. USA, 90, 6454–6458.

  • Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y and Hirai H . (1998). Blood, 92, 4003–4012.

  • Kurzrock R, Gutterman J and Talpaz M . (1988). N. Engl. J. Med., 319, 990–998.

  • Langabeer SE, Rogers JR, Harrison G, Wheatley K, Walker H, Bain BJ, Burnett AK, Goldstone AH, Linch DC and Grimwade D . (2001). Br. J. Haematol., 112, 208–211.

  • Li S, Ilaria Jr RL, Million RP, Daley GQ and Van Etten RA . (1999). J. Exp. Med., 189, 1399–1412.

  • Liu P, Tarle SA, Hajra A, Claxton DF, Marlton P, Freedman M, Siciliano MJ and Collins FS . (1993). Science, 261, 1041–1044.

  • Louz D, van den Broek M, Verbakel S, Vankan Y, van Lom K, Joosten M, Meijer D, Lowenberg B and Delwel R . (2000). Leukemia, 14, 1876–1884.

  • Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y and Ohki M . (1991). Proc. Natl. Acad. Sci. USA, 88, 10431–10434.

  • Mucenski ML, Taylor BA, Ihle JN, Hartley JW, Morse HCd, Jenkins NA and Copeland NG . (1988). Mol. Cell. Biol., 8, 301–308.

  • Myint H, Ross FM, Hall JL and Hamblin TJ . (1997). Leuk. Res., 21, 473–474.

  • Naviaux RK, Costanzi E, Haas M and Verma IM . (1996). J. Virol., 70, 5701–5705.

  • Nucifora G . (1997). Leukemia, 11, 2022–2031.

  • Nucifora G, Begy CR, Kobayashi H, Roulston D, Claxton D, Pedersen-Bjergaard J, Parganas E, Ihle JN and Rowley JD . (1994). Proc. Natl. Acad. Sci. USA, 91, 4004–4008.

  • Okuda T, Cai Z, Yang S, Lenny N, Lyu CJ, van Deursen JM, Harada H and Downing JR . (1998). Blood, 91, 3134–3143.

  • Okuda T, van Deursen J, Hiebert SW, Grosveld G and Downing JR . (1996). Cell, 84, 321–330.

  • Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, Pendergast AM, Bronson R, Aster JC, Scott ML and Baltimore D . (1998). Blood, 92, 3780–3792.

  • Phillips RL, Ernst RE, Brunk B, Ivanova N, Mahan MA, Deanehan JK, Moore KA, Overton GC and Lemischka IR . (2000). Science, 288, 1635–1640.

  • Russell M, List A, Greenberg P, Woodward S, Glinsmann B, Parganas E, Ihle J and Taetle R . (1994). Blood, 84, 1243–1248.

  • Scandura JM, Boccuni P, Cammenga J and Nimer SD . (2002). Oncogene, 21, 3422–3444.

  • Senyuk V, Chakraborty S, Mikhail FM, Zhao R, Chi Y and Nucifora G . (2002). Oncogene, 21, 3232–3240.

  • Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, Loh M, Felix C, Roy DC, Busque L, Kurnit D, Willman C, Gewirtz AM, Speck NA, Bushweller JH, Li FP, Gardiner K, Poncz M, Maris JM and Gilliland DG . (1999). Nat. Genet., 23, 166–175.

  • Sood R, Talwar-Trikha A, Chakrabarti SR and Nucifora G . (1999). Leukemia, 13, 348–357.

  • Tanaka T, Mitani K, Kurokawa M, Ogawa S, Tanaka K, Nishida J, Yazaki Y, Shibata Y and Hirai H . (1995). Mol. Cell. Biol., 15, 2383–2392.

  • Wang Q, Stacy T, Miller JD, Lewis AF, Gu TL, Huang X, Bushweller JH, Bories JC, Alt FW, Ryan G, Liu PP, Wynshaw-Boris A, Binder M, Marin-Padilla M, Sharpe AH and Speck NA . (1996). Cell, 87, 697–708.

  • Yergeau DA, Hetherington CJ, Wang Q, Zhang P, Sharpe AH, Binder M, Marin-Padilla M, Tenen DG, Speck NA and Zhang DE . (1997). Nat. Genet., 15, 303–306.

  • Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ, Burel SA, Lagasse E, Weissman IL, Akashi K and Zhang DE . (2001). Proc. Natl. Acad. Sci. USA, 98, 10398–10403.

  • Zhang X and Ren R . (1998). Blood, 92, 3829–3840.

Download references

Acknowledgements

We thank Anna Munson for technical assistance. This work was supported by National Cancer Institute Grant CA68008 and American Cancer Society research Grant RSG-02-059-01-LIB (to RR). RR is a recipient of the Leukemia and Lymphoma Society Scholar Award.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ruibao Ren.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cuenco, G., Ren, R. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice. Oncogene 23, 569–579 (2004). https://doi.org/10.1038/sj.onc.1207143

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207143

Keywords

This article is cited by

Search

Quick links